Financials · ZBIO

Zenas BioPharma Inc. (ZBIO) financials

For the twelve months ended Sep 30, 2026, Zenas BioPharma Inc. reported $11.00M of revenue and -$541.81M of net income.

Revenue, TTM
$11.00M
Revenue growth, YoY
-26.7%
Net income, TTM
-$541.81M
Net margin
-4925.5%
Free cash flow, TTM
-$242.83M
EPS, diluted, TTM
-$10.05
Cash
$177.78M
P/S
172.20
Market cap
$1.89B
Annual revenue$10.00M
FY2023FY2025
Annual net income-$377.74M
FY2023FY2025
Annual free cash flow-$172.35M
FY2023FY2025

ZBIO revenue and earnings growth

ZBIO revenueQ3 2026$10.00M

QoQ
+900.0%
FY YoY
+100.0%

ZBIO revenue was $10.00M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier and up 900.0% from the prior quarter. For the full fiscal 2025 it was $10.00M, up 100.0% from fiscal 2024.

ZBIO net incomeQ3 2026-$108.92M

ZBIO net income was -$108.92M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$51.50M a year earlier. For the full fiscal 2025 it was -$377.74M, compared with -$156.99M in fiscal 2024.

ZBIO EPSQ3 2026-$1.65

ZBIO diluted EPS was -$1.65 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$8.44.

ZBIO free cash flowQ3 2026-$57.98M

ZBIO free cash flow was -$57.98M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$41.13M a year earlier. For the full fiscal 2025 it was -$172.35M, compared with -$119.81M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Revenue$10.00M$5.00M$50.00M
Research and development$168.06M$139.14M$60.03M
Selling, general and admin$53.32M$29.75M$17.11M
Operating income-$383.06M-$163.89M-$37.15M
Interest expense$7.33M--
Pre-tax income-$377.82M-$156.56M-$36.82M
Income tax-$79.0K$429.0K$301.0K
Net income-$377.74M-$156.99M-$37.12M
EPS, basic-$8.44-$11.89-$24.25
EPS, diluted-$8.44-$11.89-$24.25
Diluted shares44.7M13.2M1.5M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Cash and equivalents$110.64M$319.83M$56.94M
Short-term investments$232.55M$31.02M-
Current assets$351.17M$355.92M$59.80M
Total assets$383.64M$369.97M$68.18M
Current liabilities$62.65M$57.29M$23.26M
Long-term debt$78.64M-$20.30M
Total debt$78.64M-$20.30M
Total liabilities$141.50M$57.51M$43.81M
Shareholders' equity$242.14M$312.46M-$225.72M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Operating cash flow-$172.33M-$119.67M-$30.53M
Capital expenditures$18.0K$131.0K$17.0K
Free cash flow-$172.35M-$119.81M-$30.55M
Investing cash flow-$251.89M-$30.55M-$17.0K
Financing cash flow$215.28M$412.96M$20.12M
Stock-based compensation$26.35M$10.82M$3.50M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Revenue growth, YoY100.0%-90.0%-
Operating margin-3830.6%-3277.8%-74.3%
Net margin-3777.4%-3139.8%-74.2%
Free cash flow margin-1723.5%-2396.1%-61.1%
Return on equity-156.0%-50.2%-
Return on assets-98.5%-42.4%-54.4%
Current ratio5.616.212.57
Debt to equity0.32--

Source: XBRL data Zenas BioPharma Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ZBIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ZBIO$11.00M-26.7%-$541.81M-4925.5%$1.89B
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$680.19B
ABBV$66.01B+10.7%$10.34B15.7%$520.65B
MRK$67.38B+4.9%$2.45B3.6%$356.13B
NVS$54.53B+8.4%$13.98B25.6%$305.69B
AZN$58.74B+8.6%$10.22B17.4%$285.36B
ABT$48.23B+10.0%$4.70B9.7%$186.10B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.18B

ZBIO FAQ

8 questions
  • What is ZBIO revenue?
    Zenas BioPharma Inc. (ZBIO) reported $11.00M of revenue for the twelve months ended Sep 30, 2026. That is down 26.7% from the year before. Revenue for fiscal 2025 was $10.00M.
  • Is ZBIO profitable?
    No. Zenas BioPharma Inc. reported a net loss of $541.81M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ZBIO have?
    Zenas BioPharma Inc. reported $177.78M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ZBIO revenue growing?
    Zenas BioPharma Inc.'s revenue changed +100.0% in fiscal 2025, to $10.00M.
  • What is ZBIO free cash flow?
    Zenas BioPharma Inc. generated -$242.83M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$242.83M less capital expenditures.
  • What is ZBIO earnings per share?
    Diluted earnings per share were -$10.05 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ZBIO last report financial results?
    The latest statements here come from Zenas BioPharma Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this ZBIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Zenas BioPharma Inc. files with the SEC. It is provided for information only and is not investment advice.